Prospective Evaluation of Residual Breast Tissue After Skin- or Nipple-Sparing Mastectomy: Results of the SKINI-Trial
This study was designed to investigate the presence of residual breast tissue (RBT) after skin-sparing mastectomy (SSM) and nipple-sparing mastectomy (NSM) and to analyse patient- and therapy-related factors associated with RBT. Skin-sparing mastectomy and NSM are increasingly used surgical procedures. Prospective data on the completeness of breast tissue resection is lacking. However, such data are crucial for assessing oncologic safety of risk-reducing and curative mastectomies.
Between April 2016 and August 2017, 99 SSM and 61 NSM were performed according to the SKINI-trial protocol, under either curative (n = 109) or risk-reducing (n = 51) indication. After breast removal, biopsies from the skin envelope (10 biopsies per SSM, 14 biopsies per NSM) were taken in predefined radial localizations and assessed histologically for the presence of RBT and of residual disease.
Residual breast tissue was detected in 82 (51.3%) mastectomies. The median RBT percentage per breast was 7.1%. Of all factors considered, only type of surgery (40.4% for SSM vs. 68.9% for NSM; P < 0.001) and surgeon (P < 0.001) were significantly associated with RBT. None of the remaining factors, e.g., skin flap necrosis, was associated significantly with RBT. Residual disease was detected in three biopsies.
Residual breast tissue is commonly observed after SSM and NSM. In contrast, invasive or in situ carcinomas are rarely found in the skin envelope. Radicality of mastectomy in this trial is not associated with increased incidence of skin flap necrosis.
ClinicalTrials.gov Identifier NCT03470909.
The authors thank the participating patients who made this study possible. The authors thank the surgical staff of the involved hospitals for their support and patience. The authors also thank A. Beccarelli, M. Brück, and M. von Wantoch for patient data registration and administration and A. Papassotiropoulos for statistical and scientific input. The study was supported by the Estée Lauder Breast Cancer Research Foundation.
Estée Lauder Breast Cancer Research Foundation.
The authors declare no conflict of interest.
- 4.Singletary SE. Skin-sparing mastectomy with immediate breast reconstruction: the M. D. Anderson Cancer Center experience. Ann Surg Oncol. 1996;3(4):411–6.Google Scholar
- 6.Carlson GW, Bostwick J, 3rd, Styblo TM, et al. Skin-sparing mastectomy. Oncologic and reconstructive considerations. Ann Surg. 1997;225(5):570–5 (discussion 575–8).Google Scholar
- 9.Hudson DA, Skoll PJ. Single-stage, autologous breast restoration. Plast Reconstr Surg. 2001;108(5):1163–71 (discussion 1172–3).Google Scholar
- 10.Gerber B, Krause A, Reimer T, et al. Skin-sparing mastectomy with conservation of the nipple-areola complex and autologous reconstruction is an oncologically safe procedure. Ann Surg. 2003;238(1):120–7.Google Scholar
- 17.Munhoz AM, Aldrighi CM, Montag E, et al. Clinical outcomes following nipple-areola-sparing mastectomy with immediate implant-based breast reconstruction: a 12-year experience with an analysis of patient and breast-related factors for complications. Breast Cancer Res Treat. 2013;140(3):545–55.CrossRefGoogle Scholar
- 22.Weber WP, Haug M, Kurzeder C, et al. Oncoplastic Breast Consortium consensus conference on nipple-sparing mastectomy. Breast Cancer Res Treat. Sep 4 2018.Google Scholar
- 34.Hadar T, Tahover E, Gekhtman D, et al. MRI demonstration of distribution and extent of residual breast tissue in skin-sparing mastectomy with immediate reconstruction. Paper presented at: 19th annual meeting 2018; Orlando, FL.Google Scholar
- 35.Pfeiler G, Farr A, Woitek R, et al. Residual breast tissue after mastectomy in non high risk and BRCA mutated patients. J Clin Oncol. 2015;33(15).Google Scholar